Chinese medicine prevention and treatment program for suspected novel coronavirus pneumonia (COVID-19): a perspective, double-blind, placebo, randomised controlled trial
Phase 1
Recruiting
- Conditions
- novel coronavirus pneumonia (COVID-19)
- Registration Number
- ITMCTR2000002963
- Lead Sponsor
- Zhejiang Chinese Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
(1) Conforming to the diagnostic criteria of suspected cases (Chiese medicine observation period) in the fourth edition of pneumonia diagnosis and treatment program for new coronavirus infection issued by the national health and health commission;
(2) Age between 14 and 80 years old;
(3) Patients informed and agreed to participate in the study.
Exclusion Criteria
(1) Patients are not suitable to take Chinese medicine decoction.
(2) Patients have other serious organ disease or mental illness;
(3) Patients allergy or have contraindications to the drugs involved in the research program.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Relief of clinical symptoms and duration;
- Secondary Outcome Measures
Name Time Method Rate of severe pneumonia or death in people who progress to 2019-nCoV pneumonia;Progression rate of 2019-nCoV pneumonia;